ISOThrive Final Phase 2 Results for MHS-1031 Announced at ACG 2026 ...
(PR-inside.com) ACG Presidential Poster Award winner for high quality, novel, unique, or interesting research HEALDSBURG, CA / ACCESS Newswire / October 12, 2026 / ISOThrive Inc. today announced final results from its Phase 2 trial of MHS-1031 in patients with non-erosive reflux disease (NERD) who experience an incompl…
Extrait seulement — cet éditeur protège son texte. Lisez le communiqué complet à la source.
Résiliable à tout moment · 99 $ CA/mois


